These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 27349449)
1. Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties. Fang JK; Xu Z; Zhang Y; Zhang W; Liu B; Fang Y; Sun T Anticancer Agents Med Chem; 2016; 16(12):1665-1672. PubMed ID: 27349449 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity. Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity. Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors. Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007 [TBL] [Abstract][Full Text] [Related]
6. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies. El-Sayed NA; Nour MS; Salem MA; Arafa RK Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778 [TBL] [Abstract][Full Text] [Related]
7. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity. Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919 [TBL] [Abstract][Full Text] [Related]
8. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers. Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Structure-Activity Relationships of Novel Diaryl Urea Derivatives as Potential EGFR Inhibitors. Jiang N; Bu Y; Wang Y; Nie M; Zhang D; Zhai X Molecules; 2016 Nov; 21(11):. PubMed ID: 27869742 [TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. George RF; Samir EM; Abdelhamed MN; Abdel-Aziz HA; Abbas SE Bioorg Chem; 2019 Mar; 83():186-197. PubMed ID: 30380447 [TBL] [Abstract][Full Text] [Related]
13. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents. Yassen AS; Elshihawy HE; Said MM; Abouzid KA Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. Aziz MW; Kamal AM; Mohamed KO; Elgendy AA Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586 [TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel gefitinib-based derivatives and their anticancer activity. Sharma MJ; Kumar MS; Murahari M; Mayur YC Arch Pharm (Weinheim); 2019 May; 352(5):e1800381. PubMed ID: 31012144 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and Anti-Proliferation Activity Evaluation of Novel 2-Chloroquinazoline as Potential EGFR-TK Inhibitors. Zheng Q; Xu XB; Jin H; Zhang W; Rao GW Chem Biodivers; 2021 Nov; 18(11):e2100478. PubMed ID: 34510749 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance. Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884 [TBL] [Abstract][Full Text] [Related]
18. Compounds Consisting of Quinazoline, Ibuprofen, and Amino Acids with Cytotoxic and Anti-Inflammatory Effects. Garduño-Villavicencio LR; Martínez-Ortega U; Ortiz-Sánchez E; Tinajero-Rodríguez JM; Hernández-Luis F ChemMedChem; 2024 May; 19(10):e202300651. PubMed ID: 38354370 [TBL] [Abstract][Full Text] [Related]
19. Novel 4-arylaminoquinazolines bearing Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043 [TBL] [Abstract][Full Text] [Related]
20. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]